SCHEMBL6041327

SCHEMBL6041327

c1ccc(-c2cc(COC3CCCCO3)on2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.52
NPC1 O15118 8/20 0.52
SMN1; SMN2 Q16637 8/20 0.52
L3MBTL1 Q9Y468 5/20 0.52
TDP1 Q9NUW8 3/20 0.52
POLB P06746 2/20 0.47
NOTUM Q6P988 2/20 0.47
MAPT P10636 4/20 0.45
HPGD P15428 1/20 0.44
STAT3 P40763 1/20 0.44
STAT1 P42224 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
IL4I1 Q96RQ9 2/20 0.44
LMNA P02545 2/20 0.43
KDM4C Q9H3R0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15919565 0.89 NAAA (0.40) RAB9ANPC1SMN1; SMN2L3MBTL1TDP1
SCHEMBL6612867 0.83 NPC1 (0.39) RAB9ANPC1SMN1; SMN2L3MBTL1TDP1
SCHEMBL6167701 0.82 NPC1 (0.44) RAB9ANPC1SMN1; SMN2L3MBTL1TDP1
SCHEMBL15919566 0.81 NAAA (0.37) RAB9ANPC1SMN1; SMN2L3MBTL1TDP1
SCHEMBL6167360 0.78 NPC1 (0.39) RAB9ANPC1MEN1KMT2A
SCHEMBL24006649 0.78 KDM4C (0.38) RAB9ANPC1L3MBTL1POLBMEN1
SCHEMBL7476046 0.77 KMT2A (0.45) RAB9ANPC1SMN1; SMN2POLBMEN1
SCHEMBL25220812 0.77 LMNA (0.43) RAB9AL3MBTL1POLBMEN1KMT2A
SCHEMBL24006607 0.76 KDM4C (0.41) RAB9ANPC1L3MBTL1MEN1KMT2A
SCHEMBL22275457 0.76 KDM4C (0.41) RAB9ANPC1L3MBTL1POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 US disclosed
EP-0863875-B1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY HOFFMANN LA ROCHE (CH) 2003-06-04 EP disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 US disclosed
EP-0863875-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1998-09-16 EP disclosed
WO-1997009311-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1997-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 RAB9A 1698/4885NPC1 418/4885SMN1; SMN2 1096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.